OKYO Pharma Management
Management criteria checks 1/4
OKYO Pharma's CEO is Gary Jacob, appointed in Jan 2021, has a tenure of 2.58 years. total yearly compensation is £1.53M, comprised of 17.5% salary and 82.5% bonuses, including company stock and options. directly owns 3.18% of the company’s shares, worth €1.04M. The average tenure of the management team and the board of directors is 2.6 years and 2.6 years respectively.
Key information
Gary Jacob
Chief executive officer
UK£1.5m
Total compensation
| CEO salary percentage | 17.5% |
| CEO tenure | 2.6yrs |
| CEO ownership | 3.2% |
| Management average tenure | 2.6yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -UK£7m |
| Jun 30 2022 | n/a | n/a | -UK£5m |
| Mar 31 2022 | UK£2m | UK£266k | -UK£4m |
| Dec 31 2021 | n/a | n/a | -UK£4m |
| Sep 30 2021 | n/a | n/a | -UK£4m |
| Jun 30 2021 | n/a | n/a | -UK£3m |
| Mar 31 2021 | UK£633k | UK£62k | -UK£3m |
Compensation vs Market: Gary's total compensation ($USD1.95M) is above average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
CEO
Gary Jacob (76 yo)
2.6yrs
Tenure
UK£1,525,565
Compensation
Dr. Gary S. Jacob, PhD, served as an Independent Director at Virpax Pharmaceuticals, Inc. since April 2020 until July 25, 2022. He had been an Independent Director of Cardiff Oncology, Inc. since February...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.6yrs | UK£1.53m | 3.18% € 1.0m | |
| Founder | no data | no data | no data | |
| Chief Financial Officer | 3yrs | no data | 0% € 0 | |
| Chief Scientific Officer | 2.4yrs | no data | 0% € 0 |
2.6yrs
Average Tenure
65yo
Average Age
Experienced Management: OK11's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.6yrs | UK£1.53m | 3.18% € 1.0m | |
| Independent Non-Executive Director | 1.7yrs | UK£14.46k | 0% € 0 | |
| Non-Executive Chairman | 2.6yrs | UK£124.85k | 57.47% € 18.8m | |
| Independent Non-Executive Director | 3.2yrs | UK£47.20k | 0% € 0 | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Senior Independent Non-Executive Director | 7.8yrs | UK£34.26k | 0.018% € 6.1k | |
| Member of Scientific Advisory Board | 3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.6yrs
Average Tenure
72yo
Average Age
Experienced Board: OK11's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/08 08:34 |
| End of Day Share Price | 2023/05/11 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OKYO Pharma Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Ashok Kumar | ThinkEquity LLC |